The Federal Trade Commission said Wednesday that 14 of 33 deals filed last year to end patent disputes between brand-name and generic-drug companies included a condition that restricts the generic-drug maker's right to launch its product in exchange for compensation from the brand-name company. Though the FTC did not name any companies in its report, it warned that pay-for-delay settlements could delay the introduction of more affordable treatments and leave consumers to foot the bill.

Full Story:
USA Today

Related Summaries